NDAORALCAPSULEPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
RETEVMO (selpercatinib) by Eli Lilly and Company is rearranged during transfection (ret) inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2020.
Drug data last refreshed 7m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETEVMO (selpercatinib) is an oral RET kinase inhibitor approved by FDA in May 2020 for treating RET-altered cancers, including medullary thyroid cancer and RET fusion-positive non-small cell lung cancer. The drug selectively inhibits the rearranged during transfection (RET) receptor tyrosine kinase, blocking oncogenic signaling in patients with RET-driven mutations.
$58MPart D
Growth12.8 years to LOEEarly-stage growth trajectory with modest current spending signals emerging opportunity; commercial teams are scaling market access and patient identification infrastructure.
Mechanism of Action
Rearranged during Transfection (RET) Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Started Jul 2024
13 enrolled
Differentiated Thyroid CancerPediatric CancerCancer+1 more
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
Started Jul 2023
28 enrolled
Healthy
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Started Mar 2023
30 enrolled
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Started Apr 2022
46 enrolled
Healthy
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Started Dec 2021
152 enrolled
Carcinoma, Non-Small-Cell Lung
Worked on RETEVMO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.